Black men twice as likely to die from prostate cancer compared to white men
the ONA take:
Black men are twice as likely to be diagnosed with, or die from, prostate cancer in their lifetime compared to white men, according to an English population study published in BMC Medicine.
Additionally, Asian men are half as likely to be diagnosed, or die from, prostate cancer in their lifetime compared to white men.
Researchers led by Alison Cooper of Prostate Cancer UK and Public Health England studied prostate cancer incidence and mortality data in England from 2008 to 2010 from a variety of sources, including Public Health England and the Office for National Statistics. In total, their sample size included 25,635,649 men, with 102,252 prostate cancer diagnoses and 26,521 deaths as a result of prostate cancer.
They found that lifetime risk of being diagnosed with prostate cancer in England was about 1 in 8 (13.3 percent) for white men, 1 in 4 (29.3 percent) for black men, and 1 in 13 (7.9 percent) for Asian men.
Risk of dying from prostate cancer in England was found to be about 1 in 24 (4.2 percent) in white men, 1 in 12 (8.7 percent) in black men, and 1 in 44 (2.3 percent) in Asian men.
Independent of ethnicity, white, black and Asian men with prostate cancer diagnosis were found to have a one third chance of dying from the disease.
Further work is needed to understand the mechanisms for the higher risk found in black men.
Black men are twice as likely to be diagnosed with, or die from, prostate cancer in their lifetime compared to white men.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
- Radiotherapy is Essential in Treating Brain Tumors But Associated With Significant Adverse Events
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|